Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise
beta
Latest Financials
Filings:
By Category
By Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
Company Exhibits:
Indentures
Material Contracts & Credit Agreements
Plans of Reorganization
Articles and Bylaws
Underwriting Agreements
SEC Edgar
C21 Investments Inc.
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
C21 Investments Inc.
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
Created by potrace 1.16, written by Peter Selinger 2001-2019
beatandraise.com
beta
Latest Financials
Filings:
Category
Date
Search Filings
Institutional Holders
beta
Earnings Transcripts
beta
Global Search
SEC Edgar
C21 Investments Inc.
SIC 2833 · Medicinal Chemicals & Botanical Products
Support
about
terms
$
CWLXF
C21 Investments Inc.
CIK:
0000831609
|
SEC Filings
Income Statement
Cash Flow
Balance Sheet
v3.26.1
Consolidated Statements of Loss and Comprehensive Loss - USD ($)
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Statement of Comprehensive Income [Abstract]
Revenue
$ 32,614,513
$ 30,117,880
Cost of sales
19,009,393
17,558,940
Gross profit
13,605,120
12,558,940
Selling, general and administrative expenses
11,326,833
11,277,284
Income from operations
2,278,287
1,281,656
Accretion expense
(372,018)
(509,871)
Gain on change in fair value of derivative liabilities
29,160
52,257
Interest expense
(187,241)
(293,675)
Loss on settlement of legal proceedings
(442,543)
0
Gain (loss) on disposal of assets
7,446
(155,692)
Other income
65,699
20,246
Net income from continuing operations before income tax expense
1,378,790
394,921
Income tax expense
(4,614,428)
(4,151,650)
Net loss from continuing operations after income tax expense
(3,235,638)
(3,756,729)
Net loss from discontinued operations after income tax expense
(8,080)
(212,813)
Net loss
(3,243,718)
(3,969,542)
Other comprehensive income:
Translation adjustment
(47,417)
133,050
Comprehensive loss
$ (3,291,135)
$ (3,836,492)
Basic loss per share from continuing operations
$ (0.03)
$ (0.03)
Diluted loss per share from continuing operations
(0.03)
(0.03)
Basic loss per share from discontinued operations
0
0
Diluted loss per share from discontinued operations
(0)
(0)
Basic loss per share
(0.03)
(0.03)
Diluted loss per share
$ (0.03)
$ (0.03)
Weighted average number of common shares outstanding - basic
117,910,795
119,794,951
Weighted average number of common shares outstanding - diluted
118,466,588
120,588,044
v3.26.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
OPERATING ACTIVITIES
Net loss from continuing operations after income tax expense
$ (3,235,638)
$ (3,756,729)
Adjustments to reconcile net loss to cash provided by operating activities:
Accretion expense
372,018
509,871
Amortization of right-of-use assets
655,818
574,686
Deferred income tax recovery
(147,496)
156,660
Depreciation and amortization
1,780,182
1,706,012
Gain on change in fair value of derivative liabilities
(29,160)
(52,257)
Interest expense
187,241
293,675
Interest and accretion income included in other income
(65,188)
0
Loss on extinguishment of EFF liability
442,543
0
(Gain) loss on disposal of assets
(7,446)
155,692
Share-based compensation
236,779
849,559
Changes in operating assets and liabilities:
Receivables
115,300
77,696
Inventory
(49,587)
(698,690)
Prepaid expenses and deposits
63,381
(53,196)
Accounts payable and accrued liabilities
335,590
(419,139)
Settlement liability
(1,100,000)
0
Income taxes payable
(1,179,137)
(7,396,432)
Uncertain tax position
3,539,212
9,822,797
Deferred revenue
(6,042)
22,332
Lease liabilities
(545,231)
(426,884)
Cash provided by operating activities of continuing operations
1,363,139
1,365,653
Cash used in operating activities of discontinued operations
(8,080)
(176,487)
INVESTING ACTIVITIES
Purchases of property and equipment
(244,838)
(406,733)
Purchases of intangible assets
0
(3,413,647)
Proceeds from disposal of assets
25,000
367,229
Cash used in investing activities of continuing operations
(219,838)
(3,453,151)
Cash provided by investing activities of discontinued operations
0
331,936
FINANCING ACTIVITIES
Proceeds from issuance of debenture units
0
2,920,562
Interest payments received on note receivable
34,000
0
Principal repayments on convertible debentures
(1,286,179)
(677,732)
Interest paid in cash
(187,241)
(293,675)
Repurchase and cancellation of shares
(103,034)
(276,730)
Cash (used in) provided by financing activities of continuing operations
(1,542,454)
1,672,425
Cash used in financing activities of discontinued operations
0
(405,253)
Effect of foreign exchange on cash
16,078
29,770
Change in cash during the year
(391,155)
(635,107)
Cash, beginning of year
2,625,461
3,260,568
Cash, end of year
2,234,306
2,625,461
Supplemental disclosure of cash flow information:
Income tax paid in cash
2,500,000
1,500,000
Interest payments received on note receivable
34,000
0
Interest paid in cash
(187,241)
293,675
Addition in right-of-use assets and lease liabilities
$ 0
$ 1,221,143
v3.26.1
Consolidated Balance Sheets - USD ($)
Mar. 31, 2026
Mar. 31, 2025
Current assets
Cash
$ 2,234,306
$ 2,625,461
Receivables
61,395
176,695
Inventory
4,590,546
4,051,425
Prepaid expenses and deposits
587,153
645,809
Note receivable - current portion
833,954
0
Assets classified as held for sale
0
4,725
Total current assets
8,307,354
7,504,115
Non-current assets
Property and equipment
2,299,350
2,665,600
Right-of-use assets
8,751,764
9,393,282
Intangible assets
6,406,481
8,092,663
Goodwill
28,541,323
28,541,323
Note receivable
0
802,766
Deferred tax asset
112,679
0
Total assets
54,418,951
56,999,749
Current liabilities
Accounts payable and accrued liabilities
1,861,171
2,148,153
Convertible promissory notes
0
1,156,259
Convertible debentures - current portion
732,638
977,817
Settlement liability - current portion
1,200,000
0
Income taxes payable
1,654,854
2,833,991
Deferred revenue
303,850
309,892
Lease liabilities - current portion
634,817
530,931
Total current liabilities
6,387,330
7,957,043
Non-current liabilities
Convertible debentures
0
710,367
Settlement liability
100,000
0
Lease liabilities
9,136,307
9,771,124
Uncertain tax position
13,362,009
9,822,797
Derivative liability
0
27,824
Deferred tax liability
0
34,817
Total liabilities
28,985,646
28,323,972
SHAREHOLDERS' EQUITY
Common stock, no par value; unlimited shares authorized; 117,836,067 and 117,996,814 shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively
107,244,066
107,006,777
Subordinate shares, no par value; unlimited shares authorized; 100,000,000 and nil shares issued and outstanding as of March 31, 2026 and March 31, 2025, respectively
72
0
Commitment to issue shares
439,443
628,141
Accumulated other comprehensive loss
(2,185,615)
(2,138,198)
Deficit
(80,064,661)
(76,820,943)
Total shareholders' equity
25,433,305
28,675,777
Total liabilities and shareholders' equity
$ 54,418,951
$ 56,999,749